ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1802

Rheumatologic Disorder Diagnostic Testing Patterns:Real World Evidence from a National Laboratory Database

David Alfego1, Quinn Hlatky2, Stanley Naides3, Karis Lee4, Jennifer Ennis5 and Kristen Clark6, 1LabCorp, San Diego, CA, 2LabCorp, Philadelphia, PA, 3Labcorp, Dana Point, CA, 4LabCorp, Orlando, FL, 5LabCorp, Chicago, IL, 6LabCorp, Raleigh, NC

Meeting: ACR Convergence 2023

Keywords: Clinical practice guidelines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1796–1826) Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatologic disorders can take years to diagnose. Diagnosis often requires a combination of specific symptoms, examination findings and laboratory testing, rather than a single test. Additionally, symptoms presenting in rheumatologic processes are often present in other common conditions, making diagnosis challenging. A common starting point is an antinuclear antibody (ANA) test, often ordered by a non-rheumatology provider, followed by a wide range of further antibody testing to narrow disorders. Here, we sought to examine patterns of post-ANA testing using real world evidence to inform order guidance opportunities and help advance diagnosis.

Methods: De-identified data from the Labcorp® testing databasewere queried for all ANA orders (both individual and panel testing) between 2011 and 2022. Any ANA order placed by a rheumatologist was excluded. Follow-up antibody testing (such as Anti-Smith, Anti-dsDNA antibodies, etc.) within 365 days post-positive ANA result (1:80 or higher) and respective positivity rates were examined. Reason for ANA ordering was evaluated via ICD-10 codes associated with the original order where the ANA was the only test run on an individual specimen to remove any conflicting ICD codes with other tests.

Results: A total of 1,834,048 distinct ANA tests were ordered by a non-rheumatology provider between 2011 and 2022 and had positive results. Of these tests, 49.7% (n=910,683) were ordered by primary care and only 11.2% of the total sample (n=204,608) were associated with patients who had any order placed by a rheumatologist within a year of the ANA. Anti-dsDNA, anti-SSA, anti-SSB, Smith and RNP antibodies were the most frequently ordered autoimmune-specific follow-up tests performed by non-rheumatologists, each representing just over 50% of the sample. Of these, RNP antibodies had the highest positivity rate (27.5%), and Smith antibodies the lowest (2.9%). Thyroglobulin antibodies were the least ordered tests (5.5% of cohort) but had one of the highest positivity rates (22.5%). Of specimens with only an ANA ordered (n=148,882), M25.50 (pain in unspecified joint, 12.6% of the cohort), R76.8 (other abnormal findings in serum, 6.7%) and R53.83 (other fatigue, 5.3%), I10 (essential primary hypertension, 3.8%) and E55.9 (Vitamin D deficiency, 3.1%) were the most frequent ICD-10s ordered but together represented only 8.1% of the total cohort.

Conclusion: There does not appear to be a clear ordering pattern of follow-up testing within a year of a positive ANA test. While more than half of the cohort received some common antibody tests like Anti-dsDNA, positivity rates were low. Interestingly, approximately 10% of the cohort had an order from a rheumatologist within a year, suggesting the majority of diagnostic workup is being done by primary care. Ordering ICD-10 codes represent suspicion for a rheumatologic process and symptoms, such as joint pain, but the frequency of hypertension and Vitamin D deficiency codes do not readily explain a reason for ordering. Results suggest the need for a guideline approach for rheumatologic disorder testing evaluation and education in the non-rheumatologic setting.

Supporting image 1

Patients with Post-Positive ANA Follow-up Testing and Subsequent Positivity Rate

Supporting image 2

Top 10 Most Frequently Used ICD_10s with ANA orders


Disclosures: D. Alfego: None; Q. Hlatky: Labcorp, 3; S. Naides: Laboratory Corporation of America Holdings (Labcorp), 3; K. Lee: None; J. Ennis: Labcorp, 3, 11; K. Clark: Labcorp, 3.

To cite this abstract in AMA style:

Alfego D, Hlatky Q, Naides S, Lee K, Ennis J, Clark K. Rheumatologic Disorder Diagnostic Testing Patterns:Real World Evidence from a National Laboratory Database [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/rheumatologic-disorder-diagnostic-testing-patternsreal-world-evidence-from-a-national-laboratory-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatologic-disorder-diagnostic-testing-patternsreal-world-evidence-from-a-national-laboratory-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology